Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H22O11 |
Molecular Weight | 342.2965 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)([C@H](O)CO)[C@H](O)[C@H](O)C=O
InChI
InChIKey=DKXNBNKWCZZMJT-QMRWEYQWSA-N
InChI=1S/C12H22O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h1,4-12,14-21H,2-3H2/t4-,5-,6-,7-,8+,9+,10-,11-,12+/m1/s1
Epilactose (4-O-beta-galactopyranosyl-D-mannnose) is a rare disaccharide in cow milk that can be synthesized from lactose by the cellobiose 2-epimerase of Ruminococcus albus. Epilactose is a promising prebiotic. Dietary supplementation with epilactose (4.5%) increased cecal wall weight and cecal contents and decreased the pH of the cecal contents in Wistar-ST rats. The number of total anaerobes tended to be greater in rats fed epilactose than in those fed the control diet. Epilactose inhibited the conversion of primary bile acids to secondary bile acids. Epilactose also increased the calcium absorption in everted small intestinal sacs. In addition, the levels of plasma total cholesterol and nonhigh-density lipoprotein cholesterol were lower in epilactose-fed rats. These results indicate that epilactose promotes calcium absorption in the small intestine and possibly lowers the risk of arteriosclerosis.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20853902
50 g/kg diets for 30 days
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
20869-27-6
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY | |||
|
128037
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY | |||
|
50468-56-9
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
ALTERNATIVE | |||
|
3515BNP809
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY | |||
|
100000090145
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY | |||
|
SUB26691
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY | |||
|
C047464
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY | |||
|
1236801
Created by
admin on Fri Dec 15 15:41:56 GMT 2023 , Edited by admin on Fri Dec 15 15:41:56 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD